Oxygen Containing Hetero Ring Patents (Class 514/99)
  • Patent number: 10166298
    Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: January 1, 2019
    Assignee: Acuitas Therapeutics, Inc.
    Inventors: Steven M. Ansell, Xinyao Du
  • Patent number: 9895304
    Abstract: Oral care compositions comprising: (a) a peroxide complex comprising a peroxide component and an N-vinyl heterocyclic polymer (e.g., poly-N-vinyl polylactam, or poly-N-vinyl-polyimide); (b) a whitening agent (e.g., hydrogen peroxide); and (c) an orally acceptable carrier. In one embodiment, the carrier comprises a film forming material. Methods are also provided for making an oral care composition comprising: (a) mixing a whitening agent, silicone adhesive and carrier fluid to form a homogenous mixture; (b) adding a peroxide complex to said homogenous mixture, wherein said complex comprises hydrogen peroxide and an N-vinyl heterocyclic polymer; and (c) mixing under vacuum.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: February 20, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Lynette A. Zaidel, Guisheng Pan, Suman K. Chopra, Prakasarao Mandadi, Michael Prencipe
  • Patent number: 9115107
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: August 25, 2015
    Assignee: AJINOMOTO CO., INC.
    Inventors: Atsushi Konishi, Munetaka Tokumasu, Tamotsu Suzuki, Takahiro Koshiba, Koji Ohsumi, Osamu Ikehara, Yuko Kodama
  • Publication number: 20150148315
    Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.
    Type: Application
    Filed: September 25, 2014
    Publication date: May 28, 2015
    Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
  • Publication number: 20150132382
    Abstract: The present invention provides compositions comprising fosfomycin or a pharmaceutically acceptable salt, solvate or prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infections, which include administering an effective amount of fosfomycin or a pharmaceutically acceptable salt, solvate or a prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya
  • Publication number: 20150126435
    Abstract: Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the E. coli sequence type 131 (ST131). Also disclosed are methods and assay kits useful in detecting the presence of the distinct subtype of E. coli and methods of treating a subject suffering from an infection from a subclone of ST131.
    Type: Application
    Filed: July 2, 2013
    Publication date: May 7, 2015
    Inventors: Lance B. Price, Evgueni V. Sokurenko, James R. Johnson
  • Patent number: 9023763
    Abstract: Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Isis Innovation Limited
    Inventors: Ram Sagar, Lucia F. Primavesi, Matthew J. Paul, Benjamin G. Davis
  • Patent number: 8993786
    Abstract: The main object of the present invention relates to a novel crystalline form of Fosemprenavir Calcium designated as Form A. Another object of the present invention relates to a process for the preparation of Crystalline Form A of Fosemprenavir Calcium. Yet another object of the present invention relates to crystalline Forma A of Fosemprenavir Calcium characterized by a PXRD diffraction having reflections at about 3.1±0.2, 4.4±0.2, 5.0±0.2, 6.3±0.2, 7.4±0.2, 8.0±0.2, 2?.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: March 31, 2015
    Assignee: Mylan Laboratories Ltd.
    Inventors: Ramakoteswara Rao Jetti, Neelima Bhagavatula, Asha Rani Gorantla
  • Patent number: 8980226
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 17, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Publication number: 20150031650
    Abstract: An ascorbic acid derivative composition of a first aspect according to the present invention consists of a salt of a compound (1) represented by a general formula (1) shown below; and a salt of a compound (2) represented by a general formula (2) shown below, wherein a ratio of the salt of the compound (2) with respect to a total amount of the salt of the compound (1) and the salt of the compound (2) is from 0.1 to 10% by mass, wherein R1 represents a linear or branched alkyl group of 6 to 20 carbon atoms, R2 represents a linear or branched alkyl group of 6 to 20 carbon atoms, and R1 and R2 are the same or are different from each other.
    Type: Application
    Filed: October 11, 2013
    Publication date: January 29, 2015
    Applicant: SHOWA DENKO K.K.
    Inventors: Keiichi Nakamura, Takanori Aoki
  • Publication number: 20150030541
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventor: Thomas E. Rogers
  • Patent number: 8940927
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: January 27, 2015
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Publication number: 20150025040
    Abstract: Crystalline Forms of fosamprenavir calcium are disclosed, processes for its preparation and pharmaceutical compositions therefrom. The process for the preparation of fosamprenavir calcium crystalline Form H1, comprises: a) suspending fosamprenavir calcium in a nitrile solvent; b) heating the suspension obtained in step (a) at reflux; c) optionally adding a solvent to the reaction mass obtained in step (b); d) cooling the reaction mass at below 35 degrees Centigrade; and e) isolating fosamprenavir calcium crystalline Form H1. Another process for the preparation of substantially pure amorphous fosamprenavir calcium, which comprises: a) dissolving fosamprenavir calcium in an ester solvent; b) a portion of solvent from the solution obtained in step (a) until at least separation of fosamprenavir calcium as solid occurs; and c) isolating substantially pure amorphous fosamprenavir calcium.
    Type: Application
    Filed: May 21, 2012
    Publication date: January 22, 2015
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Kesireddy Subash Chander Reddy, Bandi Vamsi Krishna
  • Publication number: 20150011511
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Atsushi KONISHI, Munetaka TOKUMASU, Tamotsu SUZUKI, Takahiro KOSHIBA, Koji OHSUMI, OSAMU IKEHARA, Yuko KODAMA
  • Publication number: 20150005258
    Abstract: The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 1, 2015
    Applicant: Genci Corporation
    Inventors: Shaharyar M. Khan, Robert Gadwood, Arthur Glenn Romero
  • Publication number: 20140378417
    Abstract: An object of the present invention is to provide a W/O/W emulsion having temporal stability, which comprises a water soluble active component in an inner aqueous phase, and a method for producing the same. This invention makes it possible to provide a W/O/W emulsion having temporal stability by incorporating a water soluble active component in an inner aqueous phase, a solid oil component and a silicone surfactant in an oil phase, and a water soluble polymer in an outer aqueous phase.
    Type: Application
    Filed: February 27, 2013
    Publication date: December 25, 2014
    Inventors: Iwao Tatsuguchi, Tatsuo Matsuoka
  • Patent number: 8821904
    Abstract: A topical composition and its use for the prophylaxis and the treatment of defects connected to inflammatory dermopathies. Particularly, a topical composition including at least an alum, 18-?-glycyrrhetic acid and/or one derivative thereof, and vitamin A and/or one derivative thereof, and the use of such composition for the prophylaxis and the treatment of inflammatory dermopathies, preferably of the seborrhoeic dermatitis and of those affections in which the presence of an excess of sebum occurs.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: September 2, 2014
    Assignee: Skinius S.R.L.
    Inventor: Antonino Di Pietro
  • Publication number: 20140221317
    Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 7, 2014
    Applicant: Allergan, Inc.
    Inventors: PHONG X. NGUYEN, TODD M. HEIDELBAUGH, John R. Cappiello
  • Patent number: 8771750
    Abstract: A process for delivering and/or removing metal from a biological system by loading a titanate sorbent with a biometal either before introduction into the system for delivery to a site within the system or after introduction into the system for delivery to a site where there is an excess accumulation of metal and thereafter the sorbent is loaded at the site with the excess metal and is removed from the system.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: July 8, 2014
    Assignee: Savannah River Nuclear Solutions, LLC
    Inventors: David T. Hobbs, John C. Wataha, Jill Lewis, Regina L. W. Messer
  • Publication number: 20140171359
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.
    Type: Application
    Filed: May 18, 2012
    Publication date: June 19, 2014
    Inventor: Kamon Shirakawa
  • Publication number: 20140171393
    Abstract: The present invention relates to novel aromatic thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 19, 2014
    Applicant: Allergan, Inc.
    Inventors: Phong X. Nguyen, John R. Cappiello, Todd M. Heidelbaugh
  • Publication number: 20140147516
    Abstract: Methods of determining a subject's ototoxicity risk from administration of a pharmacotherapeutic compound having an ototoxicity risk, methods of administering a pharmacotherapeutic compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays, and addressable collections for performing embodiments of the methods are provided herein.
    Type: Application
    Filed: December 3, 2013
    Publication date: May 29, 2014
    Applicant: The University of British Columbia
    Inventors: Michael R. Hayden, Bruce Carleton, Colin Ross
  • Publication number: 20140135293
    Abstract: The present invention relates to allene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 15, 2014
    Applicant: ALLERGAN, INC.
    Inventors: WENKUI K. FANG, Evelyn G. Corpuz, Ken Chow, WhaBin Im
  • Publication number: 20140107075
    Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 21, 2013
    Publication date: April 17, 2014
    Applicant: ALLERGAN, INC.
    Inventors: TODD M. HEIDELBAUGH, PHONG X. NGUYEN
  • Publication number: 20140100198
    Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Eric Oldfield, Ke Wang, Weixue Wang, Yonghui Zhang
  • Publication number: 20140080790
    Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: AJINOMOTO CO., INC.
    Inventors: Atsushi KONISHI, Munetaka Tokumasu, Tamotsu Suzuki, Takahiro Koshiba, Koji Ohsumi, Osamu Ikehara, Yuko Kodama
  • Publication number: 20140066365
    Abstract: A product comprising at least one given antibiotic and a calixarene for use as medicament.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 6, 2014
    Inventors: Marion Grare, Raphaël, Emmanuel Duval
  • Patent number: 8664204
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 4, 2014
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Publication number: 20140057876
    Abstract: The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. HEIDELBAUGH, Phong X. NGUYEN
  • Patent number: 8614179
    Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: December 24, 2013
    Assignee: E-Therapeutics PLC
    Inventors: Malcolm Philip Young, Catherine Mary Thomas
  • Publication number: 20130336902
    Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 19, 2013
    Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
  • Patent number: 8604078
    Abstract: The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. The pharmaceutical composition of this invention comprises fosfomycin trometamol, glycine, and optionally other excipients as sucralose, silice dioxide, polyvinylpyrrolidone and flavor; and is substantially free from sugars and sugar alcohols as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: December 10, 2013
    Inventor: Carlos Picornell Darder
  • Publication number: 20130316983
    Abstract: Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 28, 2013
    Applicant: ORASIS
    Inventor: ORASIS
  • Publication number: 20130296273
    Abstract: Hypoxia activated prodrugs, such as, e.g., TH-281, TH-302, and TH-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, MDS, MF, and multiple myeloma.
    Type: Application
    Filed: June 27, 2011
    Publication date: November 7, 2013
    Inventor: Karen Curd
  • Publication number: 20130295075
    Abstract: Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 7, 2013
    Applicant: ORASIS
    Inventor: Richard A. Hill
  • Publication number: 20130287718
    Abstract: A skin external preparation containing an ascorbic acid-2-phosphate derivative is characterized in that only a sodium ascorbic acid-2-phosphate-6-palmitate is formulated as the ascorbic acid-2-phosphate derivative, and the skin preparation further includes at least one betaine-type amphoteric surfactant selected from the group consisting of compounds represented by the following general formula (1) or (2) (wherein R1 represents a linear or branched alkyl group of 6 to 30 carbon atoms, and R2 represents a linear or branched alkyl group of 8 to 30 carbon atoms).
    Type: Application
    Filed: May 2, 2012
    Publication date: October 31, 2013
    Applicant: SHOWA DENKO K.K.
    Inventor: Naoko Ito
  • Publication number: 20130274229
    Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng
  • Patent number: 8541397
    Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 24, 2013
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita Bhat, Evelyn Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
  • Publication number: 20130225532
    Abstract: Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided.
    Type: Application
    Filed: May 10, 2011
    Publication date: August 29, 2013
    Applicant: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Jim-Min Fang, Yih-Shyun Edmund Cheng, Jiun-Jie Shie
  • Patent number: 8507464
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 13, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Publication number: 20130171198
    Abstract: There is proposed herein a process for production of composite antimicrobial and vulnerary preparations for external administration, featuring a higher therapeutic efficiency in case of skin and soft tissues infections treatment. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio of (25-75 mass. %):(75-25 mass. %) respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. The process is distinct in that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 40%.
    Type: Application
    Filed: May 11, 2011
    Publication date: July 4, 2013
    Inventors: Victor Lvovich Limonov, Konstantin Valentinovich Gadul, Aleksandr Valerevich Dushkin
  • Publication number: 20130164336
    Abstract: There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio from 10:1 to 75:1 respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. Its main difference is that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 25%. The so obtained mixture is used for injection preparations.
    Type: Application
    Filed: May 11, 2011
    Publication date: June 27, 2013
    Inventors: Viktor Lvovich Limonov, Konstantin Valentinovich Gaidul, Aleksandr Valerevich Dushkin
  • Publication number: 20130157982
    Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 11, 2013
    Publication date: June 20, 2013
    Applicant: ALLERGAN, INC.
    Inventor: ALLERGAN, INC.
  • Publication number: 20130150331
    Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 5, 2013
    Publication date: June 13, 2013
    Applicant: ALLERGAN, INC.
    Inventor: ALLERGAN, INC.
  • Patent number: 8409549
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 ?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: April 2, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Patent number: 8404663
    Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 26, 2013
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Evelyn G. Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
  • Publication number: 20130072451
    Abstract: A low viscosity personal care composition comprising from about 10 % to about 99% of water, from about 0.01% to about 20% of a suspended particulate material, from about 0.01% to about 5% of an acrylic polymer, wherein the composition has a viscosity of from about 80 to about 1000 mPa·s, and a pH of from about 4 to about 9, wherein the acrylic polymer provide a selection yield value of at least 0.11 Pa. An array of two or more low viscosity personal care compositions, wherein one of the personal care compositions comprises said particulate material at a level different from those in the other personal care compositions.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Inventors: Qiaolu LU, Paul (Robert) Tanner, Robert (Bao Kim) Ha
  • Patent number: 8383609
    Abstract: A new anticancer compounds of formula (1) Drugs and pharmaceutical compositions to be used in human or veterinary medicine, which include at least one compound of formula (1).
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 26, 2013
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Jean-Luc Pirat, David Virieux, Ludovic Clarion, Jean-Noël Volle, Norbert Bakalara, Marcel Mersel, Jerôme Montbrun, Henri-Jean Cristau
  • Publication number: 20130045173
    Abstract: The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a compound represented by formula (1) or a pharmacologically acceptable salt thereof: wherein, R1, R3, R4, and R6 are each independently C1-3 alkyl; and R2 and R5 are each independently a hydrogen atom or C1-3 alkyl.
    Type: Application
    Filed: October 22, 2012
    Publication date: February 21, 2013
    Applicant: SHISEDIO COMPANY LTD.
    Inventor: SHISEDIO COMPANY LTD.
  • Patent number: 8361444
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: January 29, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod